Brainstorm Cell Therapeutics Received Letter From Nasdaq Indicating Co Had Not Regained Compliance With Minimum Bid Price Requirement By April 29
Portfolio Pulse from Benzinga Newsdesk
Brainstorm Cell Therapeutics received a letter from Nasdaq indicating that the company had not regained compliance with the minimum bid price requirement by April 29, according to an SEC filing.
May 03, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Brainstorm Cell Therapeutics received a Nasdaq non-compliance notice for not meeting the minimum bid price requirement.
Receiving a non-compliance notice from Nasdaq typically has a negative impact on a company's stock price in the short term. Investors may view this as a sign of financial instability or underperformance, leading to decreased confidence and potential sell-off.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100